Swayed By Industry Opposition To 'Intended Use' Rule, FDA Definitively Delays Implementation
US FDA is considering calls to drop 'totality of circumstances' test and to clarify that mere knowledge of unapproved use does not constitute evidence the use was intended.
You may also be interested in...
Before taking over the US health department, Alex Azar helped bring landmark litigation challenging the scope of FDA’s regulatory authority under the First Amendment. Now his tenure is ending with a First Amendment defense of the agency.
Speaking at the BIO CEO & Investor Conference, US agency's No. 2 official talks about compassionate use, opioids, clinical trial design, and the agency's succession plan.
Pharma and device industries had complained that rule is overbroad, violates the First Amendment and would increase company exposure to liability.